Dosing & Administration
Oral and IV Monotherapy Dosing
With BAXDELA® (delafloxacin)
Oral or IV q12h dosing
No Oral Dosage Adjustment Required Due To:
BAXDELA is not recommended in patients with End Stage Renal Disease (ESRD) (eGFR <15 mL/min/1.73 m2), including patients on hemodialysis, due to insufficient information for dosing recommendations.
Fixed-Dosage Adjustment in IV Formulation for Patients with Severe Renal Impairment (eGFR 15-29 mL/min/1.73 m2)
- 200 mg IV q12h
OR
- 200 mg IV q12h, then switch to a 450-mg BAXDELA tablet orally q12h at the discretion of the physician
INDICATION & USAGE:
BAXDELA is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Melinta Therapeutics, LLC - Unparalleled in passion & purpose
Medical Information
For medical inquiries or to report an
adverse event, other safety-related information, or product
complaints for a company product, please contact Medical
Information.
Phone: 1-844-MED-MLNT (1-844-633-6568)
medinfo@melinta.com
www.melintamedicalinformation.com
©2021 All rights reserved. PP-BAX-US-0399 Terms of Use